Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2019-05-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: Alliance for Clinical Trials in Oncology
• Treatments: Metformin

Criteria

Inclusion Criteria

• Suspected or biopsy proven Stage IA-IIIA lung squamous cell carcinoma (SCC) (must be proven SCC at the time of surgery)

• Medically fit for surgical resection (based on surgeon assessment)

• Current or prior smoker

• Age > 18 years old

• Both Male and Female

• Willing and able to consent to study, undergo study interventions, and take study drug

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2

• Subject must start Metformin within 90 days of surgery.

Exclusion Criteria

• Currently taking metformin or other diabetic drugs

• Current or previous congestive heart failure, renal failure or liver failure

• Creatinine in Women of 1.4 or greater and Creatinine in Men of 1.5 or greater

• Existing untreated or prior cancer <5 years from diagnosis

• Received neo-adjuvant platinum-based chemotherapy or targeted therapy

• Receiving adjuvant platinum-based chemotherapy or targeted therapy after surgical resection